Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company’s Board of Directors resolved to appoint Ms. Tessie Che as Chairperson
2021.Oct.27
Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. of Resolution to lift the non-competition restrictions for new directors
2021.Oct.27
Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. of important resolutions of the 2021 annual shareholders’ meeting
2021.Oct.27
OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By Taiwan Intellectual Property Office
2021.Oct.25
Application of Investigational Device Exemption for Immunohistochemistry applied to Phase II Clinical Trial of OBI-999, has been granted by FDA
2021.Oct.21
The Globo H Antibody Drug Conjugate, OBI-999, has been granted by TFDA to proceed to Phase II Human Clinical Study
2021.Oct.13
OBI filed an Application of Phase II human clinical trial for Globo-H Antibody Drug Conjugate, OBI-999, to TFDA
2021.Sep.29
OBI Filed an Application of Investigational Device Exemption (IDE) for Phase II Cohort Expansion Human Clinical Trial for Globo H Antibody Drug Conjugate, OBI-999, to FDA
2021.Sep.09
Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the Company’s Board of Directors resolved to revise the Regulations for Issuance and Subscription of 2020 Employee Stock Options
2021.Sep.09
Announcement on behalf of Amaran Biotechnology, Inc., a major subsidiary, that the company’s Board of Directors resolved to change the date for 2021 annual shareholders’ meeting
